%0 Journal Article
%T Palliative Pharmacotherapy for Cardiovascular Disease: A Scientific Statement From the American Heart Association.
%A Di Palo KE
%A Feder S
%A Baggenstos YT
%A Cornelio CK
%A Forman DE
%A Goyal P
%A Kwak MJ
%A McIlvennan CK
%A  
%J Circ Cardiovasc Qual Outcomes
%V 0
%N 0
%D 2024 Jul 1
%M 38946532
%F 8.271
%R 10.1161/HCQ.0000000000000131
%X Cardiovascular disease exacts a heavy toll on health and quality of life and is the leading cause of death among people ≥65 years of age. Although medical, surgical, and device therapies can certainly prolong a life span, disease progression from chronic to advanced to end stage is temporally unpredictable, uncertain, and marked by worsening symptoms that result in recurrent hospitalizations and excessive health care use. Compared with other serious illnesses, medication management that incorporates a palliative approach is underused among individuals with cardiovascular disease. This scientific statement describes palliative pharmacotherapy inclusive of cardiovascular drugs and essential palliative medicines that work synergistically to control symptoms and enhance quality of life. We also summarize and clarify available evidence on the utility of guideline-directed and evidence-based medical therapies in individuals with end-stage heart failure, pulmonary arterial hypertension, coronary heart disease, and other cardiomyopathies while providing clinical considerations for de-escalating or deprescribing. Shared decision-making and goal-oriented care are emphasized and considered quintessential to the iterative process of patient-centered medication management across the spectrum of cardiovascular disease.